FINWIRES · TerminalLIVE
FINWIRES

Johnson Controls' New Business Model Showing Encouraging Signs, UBS Securities Says

By

Johnson Controls International (JCI) is in the early stages of deploying its new business model focused on improving productivity and early indications are highly encouraging, UBS Securities said in a note Monday.

The company is on track to increase revenue at a large facility to $1 billion from $250 million over the next two years without higher labor, footprint, or capital requirement, according to the note.

The company has also improved on time delivery, reduced client lead times, and decreased floor space and inventory, analysts wrote.

The brokerage said it now expects 2026 earnings per share of $4.96, compared with $4.87 previously, and also anticipates sales growth from business system initiatives.

UBS Securities boosted its price target on the stock to $180 per share from $170, while reiterating its buy rating.

Shares of Johnson Controls were up more than 5% in Tuesday trading.

Price: $141.28, Change: $+7.37, Percent Change: +5.50%

Related Articles

Wire

Toyota Motor May US Sales at 238,800 Units, Down 0.6% Year Over Year, Bloomberg Says

Toyota Motor May US Sales at 238,800 Units, Down 0.6% Year Over Year, Bloomberg Says

$TM
Wire

Revolution Medicines' Cancer Drug Darax Seen Holding Lead Over Rivals, RBC Says

Revolution Medicines' (RVMD) cancer drug daraxonrasib is likely to keep its lead over emerging competitors, as some investors may be overstating the ability of rival treatments to match its performance, RBC Capital Markets said Tuesday in a report.RBC said its analysis suggests competing drugs are unlikely to show meaningful differences from daraxonrasib, setting a high bar ahead of upcoming data in pancreatic and lung cancer. Additional results in both diseases are expected to "converge on darax's profile," reinforcing its position, the report said.RBC said it would be a buyer of Revolution shares ahead of clinical updates from other companies, arguing that more data should highlight daraxonrasib's advantages and ease concerns about competition.Because daraxonrasib is expected to play a major role in treating pancreatic cancer, a rival drug would need to be clearly better and show a different safety and efficacy profile to take meaningful market share, the report said.RBC raised its price target on Revolution stock to $182 from $165 with a rating of outperform, speculative risk.Price: $155.68, Change: $-8.00, Percent Change: -4.89%

$RVMD
Wire

Akamai, Nvidia Expand Partnership to Bring Zero Trust Security to AI Factories

Akamai Technologies (AKAM) is expanding its collaboration with Nvidia (NVDA) to bring Zero Trust security architecture to artificial intelligence factories, powering autonomous enterprise agents, the companies said Tuesday.The partnership will bring Akamai Guardicore Segmentation to the Nvidia Vera BlueField-4 STX storage architecture, which is powered by the Nvidia DOCA software platform, the companies said. The integration aims to protect data, context memory, and autonomous agents within enterprise AI infrastructure, the companies said.Akamai Guardicore Segmentation integrated with Nvidia BlueField and Nvidia DOCA is expected to be available in H2 to implement workload-aware segmentation, the companies said. The integration with the Nvidia Vera BlueField-4 STX platform is slated to launch on infrastructure partner platforms in H1 of 2027, according to a joint statement.Price: $161.86, Change: $+7.85, Percent Change: +5.10%

$AKAM$NVDA